Valitor CEO Steven Lo (L) and president and CSO Wesley Jackson

A dozen years in the mak­ing, a UC Berke­ley spin­out nabs funds to take on the eye

Large­ly fund­ed by gov­ern­ment grants for the bet­ter part of its first decade, a UC Berke­ley spin­out has se­cured a new CEO and the funds to take its re­search in­to the clin­ic in ear­ly 2024.

The biotech, named by one of the co-founder’s daugh­ters and orig­i­nal­ly scrapped to­geth­er with NIH funds in the af­ter­math of the 2008-09 fi­nan­cial cri­sis, is al­so on a mis­sion to up­end the treat­ment of wet age-re­lat­ed mac­u­lar de­gen­er­a­tion, or AMD, with an in­jectable drug that it claims could be more durable than the “800-pound go­ril­la” in the room, Genen­tech’s Lu­cen­tis and Re­gen­eron/Bay­er’s Eylea.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.